Ocular Therapeutix, Inc. (OCUL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Donald Notman Jr. | Chief Financial Officer | 630.87k | -- | -- |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer | 84.88k | -- | 1961 |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer | 621.39k | -- | 1969 |
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO | -- | -- | 1964 |
| Dr. Karen-Leigh Edwards M.B.A., Ph.D. | Chief Operations Officer | -- | -- | -- |
| Dr. Peter K. Jarrett Ph.D. | Chief Technology Officer | -- | -- | 1957 |
| Mr. Philip C. Strassburger Esq. | General Counsel | 282.61k | -- | 1960 |
| Mr. William H. Ransone II | Vice President of Global Sales & Marketing | -- | -- | -- |
| Ms. Tracy Smith | Vice President of Human Resources | -- | -- | -- |
| Mr. Steve Meyers | Chief Commercial Officer | -- | -- | -- |
Ocular Therapeutix, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 267
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Corporate Governance
Recent Events
- Apr 19, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 29, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 25, 2024S-3ASR: Offering RegistrationsSee Full Filing
- Mar 11, 202410-K: Periodic Financial ReportsSee Full Filing